Biohaven Ltd. (NYSE:BHVN – Get Free Report) Director Gregory Bailey bought 17,817 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The shares were purchased at an average cost of $22.57 per share, for a total transaction of $402,129.69. Following the acquisition, the director now owns 1,525,788 shares of the company’s stock, valued at $34,437,035.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Biohaven Stock Performance
Shares of NYSE:BHVN opened at $24.02 on Friday. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -3.24 and a beta of 0.97. Biohaven Ltd. has a 1-year low of $9.45 and a 1-year high of $27.40. The company has a 50 day moving average price of $19.93 and a 200 day moving average price of $18.87.
Biohaven (NYSE:BHVN – Get Free Report) last released its quarterly earnings data on Monday, July 31st. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.14). On average, sell-side analysts expect that Biohaven Ltd. will post -4.99 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on Biohaven
Institutional Investors Weigh In On Biohaven
Several hedge funds have recently modified their holdings of BHVN. Armistice Capital LLC raised its holdings in Biohaven by 14.7% during the 1st quarter. Armistice Capital LLC now owns 3,124,000 shares of the company’s stock worth $42,674,000 after buying an additional 400,000 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in shares of Biohaven in the 2nd quarter valued at approximately $579,000. Compass Financial Advisors LLC acquired a new position in Biohaven in the 1st quarter worth approximately $239,000. Harvest Management LLC grew its position in Biohaven by 20.1% during the 2nd quarter. Harvest Management LLC now owns 16,100 shares of the company’s stock worth $385,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Biohaven by 4.6% during the 2nd quarter. Rhumbline Advisers now owns 95,389 shares of the company’s stock valued at $2,282,000 after purchasing an additional 4,198 shares during the period. 89.60% of the stock is owned by hedge funds and other institutional investors.
About Biohaven
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases.
See Also
- Five stocks we like better than Biohaven
- What is the NASDAQ Stock Exchange?
- How To Find Value Stocks Using This Simple Filtering Method
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 10/2 – 10/6
- How to Invest in Renewable Energy
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
